Merck & Co., Inc. operates as a healthcare company worldwide.
$146.71-0.16%
报价 2026-11-06
市值
$361.96B
EV
$425.31B
PE (TTM)
121.5x
预期 PE (FY2026)
53.0x
52 周区间距高点 -6.2%
$86.75$156.45
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07仅 EPS 线✗ 收入线✓ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.0x | 3.12 → 8.95（2.9x） | 16.4 |
| FY+32028-12 | 1.1x | 3.12 → 9.95（3.2x） | 14.8 |
毛利率 75% · TTM 收入 $67302M · 基数 EPS 3.12（调整后）
利润率驱动
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| MRKMerck & Co., Inc. | $361.96B | -0.2% | +3.6% | 73.5% | 121.5x | 30.7x | 23.5x | |
| NVSNovartis AG | $307B | +0.4% | – | 76% | 20.2x | 13.5x | – | |
| AZNAstraZeneca PLC | $289.13B | -0.2% | – | 78.2% | 27.5x | 15.4x | – | |
| TMOThermo Fisher Scientific Inc. | $257.42B | +2.6% | +7.8% | 39.5% | 26.8x | 18.2x | 41.4x | |
| AMGNAmgen Inc. | $248.92B | +0.0% | +4.0% | 70.5% | 24.4x | 12.5x | 30.7x | |
| GILDGilead Sciences, Inc. | $207B | -0.4% | +4.1% | 81.1% | 20.0x | 14.5x | 21.9x | |
| ABTAbbott Laboratories | $190.22B | -3.2% | +11.9% | 57.1% | 40.7x | 22.4x | 24.9x | GARP |
| NVONovo Nordisk A/S | $177.74B | +0.0% | – | 78.2% | 10.3x | 7.2x | – | Cheap |
| PFEPfizer Inc. | $167.51B | -0.2% | +1.4% | 72.8% | 37.3x | 17.7x | 14.7x | |
| 同行中位数 | – | – | +4.1% | 74.4% | 25.6x | 15.0x | 24.9x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 | 2024-09-30 Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16.61B | $16.29B | $16.32B | $17.18B | $15.8B | $15.62B | $15.62B | $16.66B |
| Gross Margin | 73.5% | 81.9% | 70.5% | 75.6% | 75.7% | 75.1% | 75.5% | 75.5% |
| Operating Margin | -4.1% | -11.6% | 37.7% | 43.4% | 40.2% | 43% | 27.8% | 23.9% |
| Net Income | $-1.34B | $-4.24B | $2.96B | $5.79B | $4.43B | $5.08B | $3.74B | $3.16B |
| Diluted EPS | -0.54 | -1.72 | 1.19 | 2.32 | 1.76 | 2.01 | 1.48 | 1.24 |
| Operating Cash Flow | $5.37B | $3.92B | $2.86B | $7.82B | $3.29B | $2.5B | $3.45B | $9.29B |
研究材料
电话会纪要摘要
暂无纪要摘要。